Literature DB >> 9551843

Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid.

M Radatz1, K Ehlers, B Yagen, M Bialer, H Nau.   

Abstract

The teratogenic properties of valproic acid (VPA) and its analogues depend to a great extent on their chemical structure. We investigated the structure-teratogenicity relationships of VPA, its structural isomer, valnoctic acid (VCA), and their two amide analogues, valpromide (VPD) and valnoctamide (VCD), respectively. Each substance was injected (3 mmol/kg) in NMRI-mice on the morning of day 8 of gestation. Embryolethality, fetal weight and exencephaly rates were recorded on day 18 of gestation. VPA caused 53% exencephaly, VPD induced 6%, VCA and VCD produced only 1% exencephaly (control values between 0 and 1%). VPA-treated mice also had increased embryolethality rates (52%). There was no significant change of embryolethality in the other treatment groups. Pharmacokinetic studies showed that VCD was eliminated from plasma at a slower rate than VPA. Also, the residual teratogenic activity of VPD was not accounted for by the relatively small amounts of its hydrolysis product VPA. This study indicates that VPD, VCA and VCD were distinctly less teratogenic than VPA. Apparently the amidation of the free carboxylic group and/or methyl-substitution at the beta-position of the carbon chain greatly decreased the teratogenic activity of VPA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551843     DOI: 10.1016/s0920-1211(97)00095-8

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  19 in total

1.  Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities.

Authors:  Sara Ornaghi; Lawrence S Hsieh; Angélique Bordey; Patrizia Vergani; Michael J Paidas; Anthony N van den Pol
Journal:  J Neurosci       Date:  2017-06-19       Impact factor: 6.167

Review 2.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

3.  Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder.

Authors:  Hiren R Modi; Kaizong Ma; Lisa Chang; Mei Chen; Stanley I Rapoport
Journal:  Psychiatry Res       Date:  2017-04-26       Impact factor: 3.222

4.  The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.

Authors:  S Eyal; J G Lamb; M Smith-Yockman; B Yagen; E Fibach; Y Altschuler; H S White; M Bialer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

5.  Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.

Authors:  Ilan Winkler; Simcha Blotnik; Jakob Shimshoni; Boris Yagen; Marshall Devor; Meir Bialer
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

6.  Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.

Authors:  Bogdan J Wlodarczyk; Krystal Ogle; Linda Ying Lin; Meir Bialer; Richard H Finnell
Journal:  Bipolar Disord       Date:  2015-08-20       Impact factor: 6.744

7.  Valnoctamide, a non-teratogenic amide derivative of valproic acid, inhibits arachidonic acid activation in vitro by recombinant acyl-CoA synthetase-4.

Authors:  Hiren R Modi; Mireille Basselin; Stanley I Rapoport
Journal:  Bipolar Disord       Date:  2014-07-08       Impact factor: 6.744

8.  In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy.

Authors:  H Lindekens; I Smolders; G M Khan; M Bialer; G Ebinger; Y Michotte
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

9.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

10.  Mood stabilizers inhibit cytomegalovirus infection.

Authors:  Sara Ornaghi; John N Davis; Kelly L Gorres; George Miller; Michael J Paidas; Anthony N van den Pol
Journal:  Virology       Date:  2016-09-19       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.